Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI), which will become effective prior to market open on Monday, May 24, 2010.
“We are committed to advancing our pipeline programs and look forward to continued momentum as we expect to report several key milestones over the remainder of 2010, including for GDC-0449, a first-in-class Hedgehog pathway inhibitor in collaboration with Genentech, and CUDC-101, an HDAC/EGFR/Her2 inhibitor and our lead proprietary drug.”
"We are very pleased to be included in the NASDAQ Biotechnology Index, which we believe underscores Curis' consistent progress and achievements over the past year," said Dan Passeri, Curis' President and Chief Executive Officer. "We are committed to advancing our pipeline programs and look forward to continued momentum as we expect to report several key milestones over the remainder of 2010, including for GDC-0449, a first-in-class Hedgehog pathway inhibitor in collaboration with Genentech, and CUDC-101, an HDAC/EGFR/Her2 inhibitor and our lead proprietary drug."
Menarini Group signs licensing deal with Insilico for promising cancer treatment